Metraipolis › archive › dc_d120bf196616

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections — Europe PMC PMID:41592114

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41592114
DOI
10.1371/journal.ppat.1013878
License (as archived)
CC0-1.0
Archived
2026-10-06T08:26:34.219Z
SHA-256 of the archived text
e5e04934e7934cf3e047e650ee0ac9743de44893f6a6de5a8029816d2eeabcff
Stable URL of this page
https://metraipolis.com/documento/dc_d120bf196616

How to cite

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections — Europe PMC PMID:41592114 — Europe PMC (en), https://europepmc.org/article/MED/41592114 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_d120bf196616 (Metraipolis archive dc_d120bf196616, sha256 e5e04934e7934cf3e047e650ee0ac9743de44893f6a6de5a8029816d2eeabcff)
BibTeX
@misc{dcd120bf196616,
  title = {A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections — Europe PMC PMID:41592114},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41592114},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_d120bf196616; sha256 e5e04934e7934cf3e047e650ee0ac9743de44893f6a6de5a8029816d2eeabcff},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41592114. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Ebola virus (EBOV) causes recurring outbreaks, with a case fatality rate of about 40%. Currently approved vaccine and antibody therapies face major limitations, including only modest reductions in mortality and restricted accessibility due to their reliance on injection-based delivery and cold-chain transport and storage. To address these challenges, we developed a bispecific nanobody, Nanosota-EB1/EB2-Fc, composed of two nanobodies (camelid-derived single-domain antibodies, Nanosota-EB1 and Nanosota-EB2) that target distinct epitopes on the EBOV glycoprotein (GP) and are fused to a human Fc domain. Through cooperative contributions from both nanobodies, this bispecific nanobody strongly inhibits GP function and effectively overcomes the virus's decoy mechanism. A single dose provided strong protection in EBOV-infected mice, including when administered at late stages of infection. It was also effective when administered intranasally, offering a needle-free delivery option. Furthermore, its high in vitro stability indicates that it can be deployed without refrigeration. Taken together, this novel bispecific nanobody represents a promising next-generation therapeutic for EBOV, combining high potency with broad accessibility.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2026 (prima pubblicazione 2026-01-27).
Identificativi: PMID 41592114 · PMCID PMC12858065 · DOI 10.1371/journal.ppat.1013878.
Descrittori MeSH principali: Hemorrhagic Fever, Ebola; Antibodies, Bispecific; Antibodies, Viral; Ebolavirus; Single-Domain Antibodies.
Pagina: https://europepmc.org/article/MED/41592114 — https://doi.org/10.1371/journal.ppat.1013878. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T08:18:50.375Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.